Atovaquone-proguanil 250-100 100S
Ended Awarded
- Contract number
- SPE2DB26FATYW
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $3,445
Award facts
- Contract value 100% obligated
- $3,445.04 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,445.04 to DMS Pharmaceutical Group Inc. for Atovaquone-Proguanil 250-100 tablets (100 count) on October 24, 2025, with an ultimate completion date of October 27, 2025. This firm fixed-price delivery order was issued without a set-aside designation, allowing the woman-owned small business pharmaceutical wholesaler to compete on an unrestricted basis. The product will be delivered to Conshohocken, Pennsylvania and represents a routine pharmaceutical supply requirement within DLA's broader Medical Supply Chain operations supporting Department of Defense healthcare facilities.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA, designated SPE2DR under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. The IDC, awarded November 13, 2025, carries a $499.999 billion ceiling and extends through December 31, 2036, encompassing a 30-month base period with three 30-month option periods. As a prime vendor contractor within the $30.3 billion PPV-G GEN V acquisition strategy, DMS Pharmaceutical Group supplies a comprehensive range of pharmaceuticals including branded and generic prescription medications, biologics, vaccines, and medical consumables to support military medical operations worldwide. The company's established performance on numerous prior DLA delivery orders demonstrates its capability to fulfill specialized pharmaceutical requirements for the federal military medical system.
Quick answers
Who was awarded contract SPE2DB26FATYW?
SPE2DB26FATYW was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 24, 2025.
How much is contract SPE2DB26FATYW worth?
The government has obligated $3,445 on SPE2DB26FATYW.
Is contract SPE2DB26FATYW an order under another contract?
Yes. SPE2DB26FATYW is a delivery order under SPE2DB24D2106, an indefinite delivery contract.
Was contract SPE2DB26FATYW competed?
The extent of competition for SPE2DB26FATYW was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award